Capricor Therapeutics (CAPR) News Today $7.50 -0.31 (-3.97%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$7.60 +0.10 (+1.32%) As of 10/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Capricor Therapeutics (NASDAQ:CAPR) vs. Baxter International (NYSE:BAX) Financial AnalysisOctober 6 at 2:54 AM | americanbankingnews.comHead to Head Contrast: Capricor Therapeutics (NASDAQ:CAPR) and Eagleford Energy (OTCMKTS:GRUSF)October 6 at 2:46 AM | americanbankingnews.comCapricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing InvestigationOctober 3, 2025 | globenewswire.comBrokerages Set Capricor Therapeutics, Inc. (NASDAQ:CAPR) Target Price at $22.25October 2, 2025 | americanbankingnews.comCapricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory PathwaySeptember 29, 2025 | seekingalpha.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 27, 2025 | marketbeat.comCapricor Therapeutics' (CAPR) Buy Rating Reaffirmed at HC WainwrightSeptember 27, 2025 | americanbankingnews.comCapricor to submit HOPE-3 data with complete response to FDA CRLSeptember 26, 2025 | msn.comCapricor stock jumps after FDA provides path forward for DMD therapySeptember 26, 2025 | au.investing.comCapricor Therapeutics Shares Rise After Positive Type A Meeting With FDASeptember 26, 2025 | marketwatch.comHC Wainwright & Co. Reiterates Capricor Therapeutics (CAPR) Buy RecommendationSeptember 26, 2025 | msn.comCapricor readies revised FDA pitch for Duchenne cell therapySeptember 26, 2025 | finance.yahoo.comCapricor gains as FDA mulls ‘regulatory flexibility’ for lead assetSeptember 26, 2025 | msn.comCapricor Therapeutics, Inc. - Special CallSeptember 25, 2025 | seekingalpha.comHC Wainwright Reiterates "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)September 25, 2025 | marketbeat.comCapricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic DisorderSeptember 25, 2025 | msn.comCapricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A MeetingSeptember 25, 2025 | globenewswire.comCapricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing InvestigationSeptember 23, 2025 | globenewswire.comWhat is B. Riley's Estimate for CAPR Q1 Earnings?September 18, 2025 | marketbeat.comBellevue, WA family calls on FDA to approve new Duchene Muscular Dystrophy treatmentSeptember 18, 2025 | yahoo.comCapricor Therapeutics, Inc. $CAPR Shares Purchased by Goldman Sachs Group Inc.September 18, 2025 | marketbeat.comWhat is B. Riley's Estimate for CAPR Q2 Earnings?September 17, 2025 | marketbeat.comCAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 16, 2025 | globenewswire.comCAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud LawsuitSeptember 15, 2025 | prnewswire.comLost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskySeptember 15, 2025 | theglobeandmail.comFINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPRSeptember 15, 2025 | businesswire.comCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPRSeptember 15, 2025 | prnewswire.comCapricor Therapeutics, Inc. $CAPR Shares Purchased by Woodline Partners LPSeptember 15, 2025 | marketbeat.comCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRSeptember 15, 2025 | prnewswire.comCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15, 2025 | prnewswire.comCAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 14, 2025 | globenewswire.comCAPR IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class...September 14, 2025 | markets.businessinsider.comCAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPRSeptember 14, 2025 | globenewswire.comCAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action LawsuitSeptember 14, 2025 | globenewswire.comCAPR IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in ...September 14, 2025 | barrons.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsSeptember 13, 2025 | prnewswire.comCapricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC WainwrightSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRSeptember 13, 2025 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsSeptember 12, 2025 | globenewswire.comClass Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact Levi & KorsinskySeptember 12, 2025 | prnewswire.comCAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPRSeptember 11, 2025 | globenewswire.comLevi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPRSeptember 11, 2025 | globenewswire.comCapricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 ...September 11, 2025 | theglobeandmail.comCapricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPRSeptember 11, 2025 | prnewswire.comCAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action LawsuitSeptember 11, 2025 | globenewswire.comOctagon Capital Advisors LP Takes $4.27 Million Position in Capricor Therapeutics, Inc. $CAPRSeptember 11, 2025 | marketbeat.comSecurities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) - Levi & Korsinsky Reminds Investors of September 15, 2025September 10, 2025 | theglobeandmail.comCapricor Therapeutics files $300M mixed securities shelfSeptember 10, 2025 | msn.comCapricor refutes FDA’s DMD deramiocel rejection in public statementSeptember 10, 2025 | msn.comCAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud LawsuitSeptember 10, 2025 | prnewswire.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.160.55▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼415▲CAPR Articles Average Week Get the Latest News and Ratings for CAPR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Capricor Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SNDX News Today SION News Today XERS News Today TSHA News Today ZYME News Today NUVB News Today ARDX News Today AMPH News Today TRML News Today PHVS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
